The late-breaking science sessions at the AAN Annual Meeting 2026, which took place in Chicago, Illinois (USA) from 18 to 22 April, brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine.
Several presentations reported positive phase III findings, while others offered important lessons from negative studies, biomarker research and emerging therapeutic platforms.
This article covers presentations highlighted in the LS1: Late-breaking Science 1 and LS2: Late-breaking Science 2 sessions at the AAN Annual Meeting 2026:
https://touchneurology.com/insight/aan-2026-late-breaking-science-key-neurology-trial-data-clinical-insights/
